CEO

Nuclear Energy :: GE, Hitachi Sign Letter of Intent to Create a Global Alliance for Nuclear Energy Business

GE (NYSE: GE) and Hitachi, Ltd. (NYSE: HIT) (TSE: 6501) have signed a letter of intent to negotiate the formation of a global alliance that will combine their new nuclear power plant and services businesses with the goal of strengthening their existing operations, accelerating the development of new products and services, and positioning their alliance for growth in the nuclear energy industry.

Wal-Mart Adds 11 States and More Medicines to $4 Generics Prescription Program

Wal-Mart Stores, Inc., (NYSE: WMT) announced that starting today, it is rolling out its $4 generic prescription program in 11 additional states and adding 17 more prescriptions to the program. With the announcement, the expanded $4 generic prescription program will now be available in an additional 502 stores throughout Idaho, Kentucky, Maine, Massachusetts, Nebraska, Oklahoma, Rhode Island, South Carolina, Utah, Washington and West Virginia.

Wal-Mart Adds 11 States and More Medicines to $4 Generics Prescription Program

Wal-Mart Stores, Inc., (NYSE: WMT) announced that starting today, it is rolling out its $4 generic prescription program in 11 additional states and adding 17 more prescriptions to the program. With the announcement, the expanded $4 generic prescription program will now be available in an additional 502 stores throughout Idaho, Kentucky, Maine, Massachusetts, Nebraska, Oklahoma, Rhode Island, South Carolina, Utah, Washington and West Virginia.

New $15 Million Grant to Improve Student Performance in Struggling Districts Across California

The California Department of Education (CDE) and California County Superintendents Educational Services Association (CCSESA) announced today a $15.5 million investment from the Bill & Melinda Gates Foundation to increase the number of students who graduate ready for college and work by strengthening the state?s district improvement plan and offering more support to struggling districts across the state.

Hypertension :: Significant reduction in blood pressure with implantable device system

A device first implanted in the United States at the University of Rochester Medical Center as part of a clinical trial is showing a significant reduction in blood pressure in patients who suffer from severe hypertension and cannot control their condition with medications or lifestyle changes.

AstraZeneca Announces New Program That Offers Significant And Convenient Savings For Medicare Part D Enrollees

AstraZeneca announced a new program that provides significant savings to Medicare Part D beneficiaries who may have difficulty affording their medicines. Beginning Nov. 15, people who qualify and enroll will be able to go to their participating local pharmacy and immediately receive savings on AstraZeneca products, including NEXIUM? (esomeprazole), CRESTOR? (rosuvastatin), SEROQUEL? (quetiapine fumarate), TOPROL XL? (metoprolol succinate) and ARIMIDEX? (anastrozole). This is a unique offering in comparison to other patient assistance programs because it gives people convenient savings on their medicines at the pharmacy counter.

Acne :: Positive findings for Aczone in acne – QLT

QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced positive results of a Phase IV clinical trial of Aczone? in more than 50 patients with G6PD deficiency that was performed to meet a post-approval commitment requested by the FDA. The purpose of this study was to gather more information about the safety of Aczone, a prescription topical medicine, in treating patients with acne who have certain blood disorders.

Osteosarcoma :: IDM Pharma’s Mepact, mifamurtide – Junovan in the Treatment of Osteosarcoma

IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted a Marketing Authorization Application (MAA) in eCTD format (electronic common technical document) to the European Medicines Agency (EMEA) for Mepact (mifamurtide for injection), requesting approval for its use in the treatment of patients with newly diagnosed resectable high-grade osteosarcoma following surgical resection in combination with post-operative multi-agent chemotherapy. This announcement follows the October 25, 2006 submission of a New Drug Application (NDA) for Junovan (mifamurtide for injection) to the Food and Drug Administration (FDA) in the United States.